| 2024 |
Zerella, J. R., Homan, C. C., Arts, P., Lin, X., Spinelli, S. J., Venugopal, P., . . . Hahn, C. N. (2024). Germline ERG haploinsufficiency defines a new syndrome with cytopenia and hematological malignancy predisposition. Blood, 144(17), 1765-1780.
DOI Scopus9 WoS8 Europe PMC6 |
| 2018 |
Branford, S., Wang, P., Yeung, D. T., Thomson, D., Purins, A., Wadham, C., . . . Hughes, T. P. (2018). Integrative genomic analysis reveals cancer-associated mutations at diagnosis of CML in patients with high-risk disease. Blood, 132(9), 948-961.
DOI Scopus169 WoS158 Europe PMC140 |
| 2017 |
Casolari, D., Nguyen, T., Butcher, C., Iarossi, D., Hahn, C., Bray, S., . . . D'Andrea, R. (2017). A novel, somatic, transforming mutation in the extracellular domain of epidermal growth factor receptor identified in myeloproliferative neoplasm. Scientific Reports, 7(1), 2467-1-2467-9.
DOI Scopus6 WoS6 Europe PMC7 |
| 2017 |
Marum, J., Yeung, D., Purins, L., Reynolds, J., Parker, W., Stangl, D., . . . Branford, S. (2017). ASXL1 and BIM germ line variants predict response and identify CML patients with the greatest risk of imatinib failure. Blood Advances, 1(18), 1369-1381.
DOI Scopus21 WoS17 Europe PMC20 |
| 2016 |
Parker, W., Yeung, D., Yeoman, A., Altamura, H., Jamison, B., Field, C., . . . Branford, S. (2016). The impact of multiple low-level BCR-ABL1 mutations on response to ponatinib. Blood, 127(15), 1870-1880.
DOI Scopus60 WoS57 Europe PMC51 |
| 2015 |
Hahn, C., Ross, D., Feng, J., Beligaswatte, A., Hiwase, D., Parker, W., . . . Scott, H. (2015). A tale of two siblings: two cases of AML arising from a single pre-leukemic DNMT3A mutant clone. Leukemia, 29(10), 2101-2104.
DOI Scopus29 WoS26 Europe PMC28 |
| 2014 |
Parker, W., Phillis, S., Yeung, D., Hughes, T., Scott, H., & Branford, S. (2014). Many BCR-ABL1 compound mutations reported in chronic myeloid leukemia patients may actually be artifacts due to PCR-mediated recombination. Blood, 124(1), 153-155.
DOI Scopus28 WoS26 Europe PMC23 |
